株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬剤溶出ステントの世界市場

Drug-Eluting Stents

発行 Global Industry Analysts, Inc. 商品コード 243052
出版日 ページ情報 英文 184 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.17円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
薬剤溶出ステントの世界市場 Drug-Eluting Stents
出版日: 2017年01月01日 ページ情報: 英文 184 Pages
概要

当レポートでは、世界の薬剤溶出性ステントの市場を調査し、市場および製品の概要、最新の産業動向と市場成長への各種影響因子の分析、冠動脈ステントの概要、新製品の発売・承認などの動向、企業および企業間の取り組み、主要企業のプロファイル、世界および主要地域・国別の市場動向と市場規模の推移と予測などをまとめています。

第1部 イントロダクション・調査手法・製品の定義

第2部 エグゼクティブサマリー

第1章 産業概要

  • 冠動脈ステント市場:はじめに
  • 主な市場成長推進因子・抑制因子
  • 競合シナリオ
  • J&Jの市場撤退
  • 薬剤溶出性ステントの進化
  • 薬剤溶出性ステントの比較分析:物理パラメーター別
  • 生体吸収性ステント
  • 生分解性ポリマーによる新しいステント
  • 生体吸収性スカフォールド:潜在的ゲームチェンジャー
  • 重要な臨床研究・イノベーション、など

第2章 マクロ的成長推進因子

  • 高齢化:主な市場推進因子
  • 高齢化人口の統計:重要な市場機会指標
  • 糖尿病の高い罹患率:心臓手術・ステント需要を推進

第3章 冠動脈ステント:分析

  • 心血管疾患:概要
  • 冠動脈心疾患
  • 冠動脈疾患の治療オプション
  • 経皮的冠動脈形成術 (PTCA)
  • 冠動脈バイパス術 (CABG)
  • 冠動脈ステント
  • 冠動脈ステントの仕組み:はじめに
  • ステント留置のリスクと問題
  • 再狭窄:主な課題
  • DESのコストと価格
  • DESのコスト分析、など

第4章 製品の発売・承認

  • MicroPort Medical:アルゼンチンでのFirehawk® DESの販売承認を取得
  • Biotronik:Orsiro Hybrid DESのバイオステム臨床試験に着手
  • Boston ScientificのEluvia DES System:CEマークを取得、など

第5章 近年の業界の動き

  • Cordis:Biosensors Internationalとの冠動脈ステントの販売契約に合意
  • MicroPort Scientific:CordisからDESのアセットおよびIPを取得

第6章 世界の主要企業

  • Abbott Laboratories (米国)
  • AlviMedica (トルコ)
  • Arterius Limited (英国)
  • B. Braun Melsungen AG (ドイツ)
  • Biosensors International Group, Ltd. (シンガポール)
  • Shandong JW Medical Systems LTD. (中国)
  • Biotronik SE & Co. KG (ドイツ)
  • Boston Scientific Corporation (米国)
  • Cook Medical Inc. (米国)
  • Elixir Medical Corp. (米国)
  • 京都医療設計 (日本)
  • Lepu Medical Technology (Beijing) Co., Ltd. (中国)
  • Medtronic plc (Republic of アイルランド)
  • Micell Technologies, Inc. (米国)
  • Opto Circuits (インド) Ltd (インド)
  • Eurocor GmbH (ドイツ)
  • OrbusNeich Medical Company Limited (香港)
  • QualiMed (ドイツ)
  • Shanghai MicroPort Medical (Group) Co., Ltd. (中国)
  • Sino Medical Sciences Technology Inc. (中国)
  • STENTYS SA (フランス)
  • テルモ (日本)

第7章 世界市場の展望

第3部 市場分析

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他
  • アジア太平洋
    • 中国
    • インド
    • その他
  • ラテンアメリカ
  • その他の地域

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-1407

This report analyzes the worldwide markets for Drug-Eluting Stents in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 35 companies including many key and niche players such as -

  • Abbott Laboratories
  • AlviMedica
  • Arterius Limited
  • B. Braun Melsungen AG
  • Biosensors International Group, Ltd.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Coronary Stents Market - A Prelude
  • Key Market Drivers & Restraints
  • Competitive Scenario
  • J&J Exit from DES Market Improves Prospects for Competitors
    • Table 1: Leading Players in the Global Drug-Eluting Stents Market (2015): Percentage Share Breakdown of Revenue for Abbott Laboratories, Boston Scientific, and Medtronic (includes corresponding Graph/Chart)
  • Evolution of the Drug-Eluting Stent
  • Evolution of Drug-Eluting Stents (DES) Over the Years
  • Comparative Analysis of Drug-Eluting Stents in Terms of Physical Parameters
  • Bioabsorbable Stents
  • New Stents with Biodegradable Polymers
  • Completely Bioresorbable Scaffolds: Potential Game-Changer
  • Noteworthy Clinical Studies and Innovations
  • Study Proves Efficacy of Very Thin Strut DES On Par with Durable Polymer Stents
  • Drug-Eluting Stents and Drug-Coated Balloons for Non-Coronary Indications
  • DES for Large Sized Arteries
  • Addressing the Unmet Challenges in Patients with Diabetes
  • Biosensors Commercializes BMX-J DES System
  • SLENDER DES Set to Downsize the Future of Interventional Cardiology
  • Other Novel DES Launches
  • Researchers at University of Strathclyde Evaluate VAN 10-4 Small Molecule
  • DES Safe for Vein Grafts Procedures

2. MACRO GROWTH DRIVERS

  • Aging - A Key Market Driver
  • Global Aging Population Demographic Statistics: Key Opportunity Indicator
    • Table 2: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 3: Global Population by Age-Group: Percentage Change Over the Period 2010-2050 (includes corresponding Graph/Chart)
    • Table 4: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart)
    • Table 5: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    • Table 6: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
  • High Diabetes Incidence Worldwide Drives Demand for Cardiac Surgery and Stents
    • Table 7: Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)
    • Table 8: Global Prevalence (%) of Diabetes in Adults (20-79) by Region (2015 & 2040) (includes corresponding Graph/Chart)
    • Table 9: Global Prevalence of Diabetes - Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2015 & 2040 (includes corresponding Graph/Chart)
    • Table 10: Worldwide Diabetes Prevalence (%) in Adults by Age Group and Gender (2015) (includes corresponding Graph/Chart)
    • Table 11: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2015 & 2040 (includes corresponding Graph/Chart)

3. CORONARY STENTING - AN INSIGHT

  • Cardiovascular Diseases - A Brief Description
  • Coronary Heart Disease
  • Treatment Options for Coronary Artery Disease
  • Percutaneous Transluminal Coronary Angioplasty (PTCA)
  • Coronary Artery Bypass Graft (CABG)
  • Coronary Stenting
  • How is Coronary Stenting Performed - Procedure
  • Risks and Problems Associated with Placing a Stent
  • Restenosis - A Major Challenge
  • Cost and Price Economics of DES
  • Cost Evaluation of DES
  • Impact of DES on Indirect Costs

4. PRODUCT LAUNCHES & APPROVALS

  • MicroPort Medical Receives Marketing Approval in Argentina for Firehawk(r) DES
  • MicroPort Medical's Firehawk(r) DES Receives Marketing Approval in Brazil
  • Biotronik Launches Biostem Clinical Trial for Orsiro Hybrid DES
  • Boston Scientific's Eluvia DES System Receives CE Mark
  • STENTYS Enters into Commercialization Agreements in Europe for below-the-knee arterial DES
  • Medtronic Launches Expanded Sizes of Onyx DES and Expands Indications
  • Svelte Medical Launches SLENDER Coronary Stent System in Europe
  • Boston Scientific Receives FDA Approval for SYNERGY(tm) DES System
  • Medtronic Launches Resolute Onyx(tm) DES in India
  • BIOTRONIK Announces Positive Clinical Trial Data of Orsiro Hybrid DES
  • Medtronic Begins Clinical Studies for Resolute Onyx(tm) DES in the US
  • Alvimedica's Cre8(tm) DES Receives CE Mark
  • Medtronic Announces CE Mark Approval and International Launch of Resolute Onyx(tm) DES
  • Cook Medical Launches Zilver PTX DES in Canada
  • Boston Scientific Launches Promus PREMIER(tm) DES in Japan
  • Terumo Corporation Receives CE Mark Approval for Ultimaster DES

5. RECENT INDUSTRY ACTIVITY

  • Cordis Enters into Coronary Stent Sales Agreement with Biosensors International
  • MicroPort Scientific Acquires DES Assets and Intellectual Property from Cordis

6. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (US)
  • AlviMedica (Turkey)
  • Arterius Limited (UK)
  • B. Braun Melsungen AG (Germany)
  • Biosensors International Group, Ltd. (Singapore)
  • Shandong JW Medical Systems LTD. (China)
  • Biotronik SE & Co. KG (Germany)
  • Boston Scientific Corporation (US)
  • Cook Medical Inc. (US)
  • Elixir Medical Corp. (US)
  • KYOTO MEDICAL PLANNING Co., Ltd. (Japan)
  • Lepu Medical Technology (Beijing) Co., Ltd. (China)
  • Medtronic plc (Republic of Ireland)
  • Micell Technologies, Inc. (US)
  • Opto Circuits (India) Ltd (India)
  • Eurocor GmbH (Germany)
  • OrbusNeich Medical Company Limited (Hong Kong)
  • QualiMed (Germany)
  • Shanghai MicroPort Medical (Group) Co., Ltd. (China)
  • Sino Medical Sciences Technology Inc. (China)
  • STENTYS SA (France)
  • Terumo Corporation (Japan)

7. GLOBAL MARKET PERSPECTIVE

    • Table 12: World Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 13: World Historic Review for Drug-Eluting Stents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 14: World 14-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Market Outlook
    • Aging Population Statistics & Diabetes Statistics: Key Opportunity Indicators
    • Table 15: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 16: Cardiovascular Disease Incidence in the US by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart)
    • Table 17: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)
    • Table 18: Diabetes and Population Statistics in North America and Caribbean Region (2015 & 2040) (includes corresponding Graph/Chart)
    • Table 19: Diabetes Statistics in the US (2015) - Number of Adults with Diabetes (in 000s), Number of Adults with Undiagnosed Diabetes (in 000s), Diabetes Prevalence (%) and Number of Diabetes-Related Deaths (in '000s)
    • Competition
    • Table 20: Leading Players in the US Drug-Eluting Stents Market (2015): Percentage Share Breakdown of Revenue for Abbott Laboratories, Boston Scientific, and Medtronic (includes corresponding Graph/Chart)
      • Wyeth and Cordis Settle Patents Infringement Dispute with Abbott
    • Product Launches
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 21: US Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 22: US Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 24: Canadian Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Product Launches
    • Select Key Players
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 26: Japanese Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analysis
    • Table 27: European Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 28: European Historic Review for Drug-Eluting Stents by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 29: European 14-Year Perspective for Drug-Eluting Stents by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Product Launch
    • STENTYS SA: Key France-Based Player
  • B. Market Analytics
    • Table 30: French Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: French Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Product Launches
    • Select Key Players
  • B. Market Analytics
    • Table 32: German Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: German Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 34: Italian Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: Italian Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Arterius Limited: Key UK-Based Player
  • B. Market Analytics
    • Table 36: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 37: UK Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 38: Spanish Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 39: Spanish Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 40: Russian Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: Russian Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Product Launches
    • Select Key Players
  • B. Market Analytics
    • Table 42: Rest of European Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 43: Rest of European Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Table 44: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 45: Asia-Pacific Historic Review for Drug-Eluting Stents by Geographic Region/ Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 46: Asia-Pacific 14-Year Perspective for Drug-Eluting Stents by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • China: Local Players Dominate DES Market
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 47: Chinese Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 48: Chinese Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • India: Cap on Prices of DES and BMS
    • Product Launch
    • Key Player
  • B. Market Analytics
    • Table 49: Indian Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 50: Indian Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Select Key Players
  • B. Market Analytics
    • Table 51: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 52: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 53: Latin American Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 54: Latin American Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Select Key Players
  • B. Market Analytics
    • Table 55: Rest of World Recent Past, Current & Future Analysis for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 56: Rest of World Historic Review for Drug-Eluting Stents Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top